Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
75.36%
Operating Margin
81.81%
Net Margin
49.58%
Efficiency Metrics
Revenue per Expense Ratio
1.53
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
81.27%
Income Tax Rate
0.00%
EPS
0.3200000000
Balance Sheet Analysis
Current Ratio
0.08
Cash Ratio
0.00
Working Capital
$-113,261.96B
Debt to Equity
0.81
Debt to Assets
44.29%
Equity Ratio
54.49%
Cash Flow Analysis
Operating Cash Flow Ratio
76.86%
Free Cash Flow Ratio
76.86%
CapEx to Revenue
0.00%
Dividends Paid
$28.62M
Stock Buybacks
$94,296.08B
Total Shareholder Returns
$94,296.10B
Cash Position Change
-36.35%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 29.67%
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
142.72%
Net Income
117.61%
EPS
116.24%
Operating Income
-14.49%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-6.66%
Operating Cash Flow
222.47%
Free Cash Flow
222.47%
Balance Sheet Health
Assets
-15.34%
Debt
-34.00%
Book Value per Share
0.69%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
29.67%
Shares Outstanding
8.36%
Long Term Trends
3Y Revenue/Share
476.36%
5Y Revenue/Share
680.35%
3Y Dividend/Share
-12.76%
5Y Dividend/Share
-33.23%